Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. They believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. The company is advancing its lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. They expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing its proprietary platform, they are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia.
Home Biosciences is a European venture builder dedicated to biotech.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.
Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Lycia Therapeutics is the operator of a biotechnology firm that aims to research and produce first-in-class therapies. The company's lysosomal targeting chimeras (LYTACs) platform is used to develop therapeutics that degrade extracellular and membrane-bound proteins that drive a variety of difficult-to-treat diseases, such as cancer and autoimmune conditions, allowing doctors to obtain drugs to cure patients.
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.
Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. They believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. The company is advancing its lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. They expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing its proprietary platform, they are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia.
aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
PacBio designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.